Abstract
In our issue of September 18, we discussed the use of vasoconstrictor drugs in myocardial infarction (Drug Ther. Bull. p. 73), pointing out the theoretical reasons for doubting their advisability, though many clinicians think that noradrenaline is of value. Since then two papers have appeared which reinforce our arguments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
